Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2010

Open Access 01-12-2010 | Research article

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Authors: Laurent Coudeville, Fabrice Bailleux, Benjamin Riche, Françoise Megas, Philippe Andre, René Ecochard

Published in: BMC Medical Research Methodology | Issue 1/2010

Login to get access

Abstract

Background

Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.

Methods

We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.

Results

A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.

Conclusion

Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.
Appendix
Available only for authorised users
Literature
2.
go back to reference Palmer DF, Dowdle WR, Coleman MT, Schild GC: Advanced laboratory technicals for immunological diagnostic. 1975, US Department of Health Palmer DF, Dowdle WR, Coleman MT, Schild GC: Advanced laboratory technicals for immunological diagnostic. 1975, US Department of Health
3.
go back to reference Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. EMEA. 1997 Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. EMEA. 1997
4.
go back to reference Wood JM, Levandowski RA: The influenza vaccine licensing process. Vaccine. 2003, 21: 1786-1788. 10.1016/S0264-410X(03)00073-2.CrossRefPubMed Wood JM, Levandowski RA: The influenza vaccine licensing process. Vaccine. 2003, 21: 1786-1788. 10.1016/S0264-410X(03)00073-2.CrossRefPubMed
5.
go back to reference Hobson D, Curry RL, Beare AS, Ward-Gardner A: The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972, 70: 767-777.CrossRef Hobson D, Curry RL, Beare AS, Ward-Gardner A: The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972, 70: 767-777.CrossRef
6.
go back to reference Hannoun C, Megas F, Piercy J: Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004, 103: 133-138. 10.1016/j.virusres.2004.02.025.CrossRefPubMed Hannoun C, Megas F, Piercy J: Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004, 103: 133-138. 10.1016/j.virusres.2004.02.025.CrossRefPubMed
7.
go back to reference Gilbert PB, Qin L, Self SG: Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med. 2008, 27: 4758-4778. 10.1002/sim.3122.CrossRefPubMedPubMedCentral Gilbert PB, Qin L, Self SG: Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med. 2008, 27: 4758-4778. 10.1002/sim.3122.CrossRefPubMedPubMedCentral
8.
go back to reference Salk JE, Menke WJ, Francis T: A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am J Hyg. 1945, 42: 57-93. Salk JE, Menke WJ, Francis T: A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am J Hyg. 1945, 42: 57-93.
9.
go back to reference Riley S, Wu JT, Leung GM: Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. PLoS Med. 2007, 4: e218-10.1371/journal.pmed.0040218.CrossRefPubMedPubMedCentral Riley S, Wu JT, Leung GM: Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. PLoS Med. 2007, 4: e218-10.1371/journal.pmed.0040218.CrossRefPubMedPubMedCentral
10.
go back to reference Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989, 8: 431-440. 10.1002/sim.4780080407.CrossRefPubMed Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989, 8: 431-440. 10.1002/sim.4780080407.CrossRefPubMed
11.
go back to reference Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992, 11: 167-178. 10.1002/sim.4780110204.CrossRefPubMed Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992, 11: 167-178. 10.1002/sim.4780110204.CrossRefPubMed
12.
go back to reference De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al: Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials. 2001, 22: 485-502. 10.1016/S0197-2456(01)00153-2.CrossRefPubMed De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al: Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials. 2001, 22: 485-502. 10.1016/S0197-2456(01)00153-2.CrossRefPubMed
13.
go back to reference Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H: The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000, 1: 49-67. 10.1093/biostatistics/1.1.49.CrossRefPubMed Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H: The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000, 1: 49-67. 10.1093/biostatistics/1.1.49.CrossRefPubMed
14.
go back to reference Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG: A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007, 196: 1304-1312. 10.1086/522428.CrossRefPubMed Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG: A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007, 196: 1304-1312. 10.1086/522428.CrossRefPubMed
15.
go back to reference Molenberghs G, Burzykowski T, Alonso A, Buyse M: A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res. 2004, 13: 177-206.PubMed Molenberghs G, Burzykowski T, Alonso A, Buyse M: A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res. 2004, 13: 177-206.PubMed
16.
go back to reference Dunning AJ: A model for immunological correlates of protection. Stat Med. 2006, 25: 1485-1497. 10.1002/sim.2282.CrossRefPubMed Dunning AJ: A model for immunological correlates of protection. Stat Med. 2006, 25: 1485-1497. 10.1002/sim.2282.CrossRefPubMed
17.
go back to reference Kohberger RC, Jemiolo D, Noriega F: Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine. 2008, 26: 3516-3521. 10.1016/j.vaccine.2008.04.016.CrossRefPubMed Kohberger RC, Jemiolo D, Noriega F: Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine. 2008, 26: 3516-3521. 10.1016/j.vaccine.2008.04.016.CrossRefPubMed
18.
go back to reference Qin L, Gilbert P, Follman D, Li D: Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model. The annals of applied statistics. 2008, 2: 386-407. 10.1214/07-AOAS132.CrossRefPubMedPubMedCentral Qin L, Gilbert P, Follman D, Li D: Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model. The annals of applied statistics. 2008, 2: 386-407. 10.1214/07-AOAS132.CrossRefPubMedPubMedCentral
19.
go back to reference Tanner MA, Wong WH: The calculation of posterior distributions by data augmentation. J Am Stat Assoc. 1987, 82: 528-550. 10.2307/2289457.CrossRef Tanner MA, Wong WH: The calculation of posterior distributions by data augmentation. J Am Stat Assoc. 1987, 82: 528-550. 10.2307/2289457.CrossRef
20.
go back to reference Lunn DJ, Thomas A, Best N, Spiegelhalter D: a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000, 10: 325-337. 10.1023/A:1008929526011.CrossRef Lunn DJ, Thomas A, Best N, Spiegelhalter D: a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000, 10: 325-337. 10.1023/A:1008929526011.CrossRef
21.
go back to reference Brooks SP, Gelman A: Alternative methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics. 1998, 7: 434-455. 10.2307/1390675. Brooks SP, Gelman A: Alternative methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics. 1998, 7: 434-455. 10.2307/1390675.
22.
go back to reference Gupta AK, Nadarajah S: Handbook of Beta Distribution and Its Applications. 2004, New York: Marcel Dekker Gupta AK, Nadarajah S: Handbook of Beta Distribution and Its Applications. 2004, New York: Marcel Dekker
23.
go back to reference Spiegelhalter D, Best N, Carlin B, Linde Van Der A: Bayesian measures of model complexity and fit (with discussion). Journal of the Royal Statistical Society, Series B (Statistical Methodology). 2002, 64: 583-639. 10.1111/1467-9868.00353.CrossRef Spiegelhalter D, Best N, Carlin B, Linde Van Der A: Bayesian measures of model complexity and fit (with discussion). Journal of the Royal Statistical Society, Series B (Statistical Methodology). 2002, 64: 583-639. 10.1111/1467-9868.00353.CrossRef
24.
go back to reference Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, Goto S, et al: Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine. 1997, 15: 962-967. 10.1016/S0264-410X(96)00302-7.CrossRefPubMed Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, Goto S, et al: Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine. 1997, 15: 962-967. 10.1016/S0264-410X(96)00302-7.CrossRefPubMed
25.
go back to reference de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD: Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003, 115: 63-73. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD: Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003, 115: 63-73.
26.
go back to reference Plotkin SA: Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001, 20: 63-75. 10.1097/00006454-200101000-00013.CrossRefPubMed Plotkin SA: Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001, 20: 63-75. 10.1097/00006454-200101000-00013.CrossRefPubMed
27.
go back to reference McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al: T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006, 176: 6333-6339.CrossRefPubMed McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al: T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006, 176: 6333-6339.CrossRefPubMed
28.
go back to reference Nauta JJ, Beyer WE, Osterhaus AD: On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals. 2009, 37: 216-221. 10.1016/j.biologicals.2009.02.002.CrossRefPubMed Nauta JJ, Beyer WE, Osterhaus AD: On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals. 2009, 37: 216-221. 10.1016/j.biologicals.2009.02.002.CrossRefPubMed
29.
go back to reference Wood JM, Gaines-Das RE, Taylor J, Chakraverty P: Comparison of influenza serological techniques by international collaborative study. Vaccine. 1994, 12: 167-174. 10.1016/0264-410X(94)90056-6.CrossRefPubMed Wood JM, Gaines-Das RE, Taylor J, Chakraverty P: Comparison of influenza serological techniques by international collaborative study. Vaccine. 1994, 12: 167-174. 10.1016/0264-410X(94)90056-6.CrossRefPubMed
30.
go back to reference Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD: Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res. 2004, 103: 125-132. 10.1016/j.virusres.2004.02.024.CrossRefPubMed Beyer WE, Palache AM, Luchters G, Nauta J, Osterhaus AD: Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res. 2004, 103: 125-132. 10.1016/j.virusres.2004.02.024.CrossRefPubMed
31.
go back to reference Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006, 367: 1657-1664. 10.1016/S0140-6736(06)68656-X.CrossRefPubMed Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al: Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006, 367: 1657-1664. 10.1016/S0140-6736(06)68656-X.CrossRefPubMed
32.
go back to reference Bell JA, Ward TG, Kapikian AZ, Shelokov A, Reichelderfer TE, Huebner RJ: Artificially induced Asian influenza in vaccinated and unvaccinated volunteers. J Am Med Assoc. 1957, 165: 1366-1373.CrossRefPubMed Bell JA, Ward TG, Kapikian AZ, Shelokov A, Reichelderfer TE, Huebner RJ: Artificially induced Asian influenza in vaccinated and unvaccinated volunteers. J Am Med Assoc. 1957, 165: 1366-1373.CrossRefPubMed
33.
go back to reference Clark A, Potter CW, Jennings R, Nicholl JP, Langrick AF, Schild GC, et al: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J Hyg (Lond). 1983, 90: 351-359.CrossRef Clark A, Potter CW, Jennings R, Nicholl JP, Langrick AF, Schild GC, et al: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J Hyg (Lond). 1983, 90: 351-359.CrossRef
34.
go back to reference Clark A, Potter CW, Jennings R, Nicholl JP, Langrick AF, Schild GC, et al: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg (Lond). 1983, 90: 361-370.CrossRef Clark A, Potter CW, Jennings R, Nicholl JP, Langrick AF, Schild GC, et al: A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg (Lond). 1983, 90: 361-370.CrossRef
35.
go back to reference Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC: Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J. 1973, 49: 159-163. 10.1136/pgmj.49.569.159.CrossRefPubMedPubMedCentral Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC: Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J. 1973, 49: 159-163. 10.1136/pgmj.49.569.159.CrossRefPubMedPubMedCentral
36.
go back to reference Eaton MD, Meiklejohn G: Vaccination against Influenza. A study in California during the epidemic of 1943-44. Am J Hyg. 1945, 42: 28-44. Eaton MD, Meiklejohn G: Vaccination against Influenza. A study in California during the epidemic of 1943-44. Am J Hyg. 1945, 42: 28-44.
37.
38.
go back to reference Farnik J, Bruj J: An outbreak of influenza A2 in a population with a known antibody profile. J Infect Dis. 1966, 116: 425-428.CrossRefPubMed Farnik J, Bruj J: An outbreak of influenza A2 in a population with a known antibody profile. J Infect Dis. 1966, 116: 425-428.CrossRefPubMed
39.
go back to reference Fox JP, Cooney MK, Hall CE, Foy HM: Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol. 1982, 116: 228-242.PubMed Fox JP, Cooney MK, Hall CE, Foy HM: Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol. 1982, 116: 228-242.PubMed
40.
go back to reference Goodeve A, Potter CW, Clark A, Jennings R, Schild GC, Yetts R: A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Lond). 1983, 90: 107-115.CrossRef Goodeve A, Potter CW, Clark A, Jennings R, Schild GC, Yetts R: A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Lond). 1983, 90: 107-115.CrossRef
41.
go back to reference Greenberg SB, Couch RB, Kasel JA: An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness. Am J Epidemiol. 1974, 100: 209-215.PubMed Greenberg SB, Couch RB, Kasel JA: An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness. Am J Epidemiol. 1974, 100: 209-215.PubMed
42.
go back to reference Meiklejohn G, Weiss DL, Shragg RI, Lennette EH: Evaluation of monovalent influenza virus vaccines. I. Observations on antibody response following vaccination. Am J Hyg. 1952, 55: 1-11.PubMed Meiklejohn G, Weiss DL, Shragg RI, Lennette EH: Evaluation of monovalent influenza virus vaccines. I. Observations on antibody response following vaccination. Am J Hyg. 1952, 55: 1-11.PubMed
43.
go back to reference Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG: Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond). 1977, 79: 321-332.CrossRef Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG: Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond). 1977, 79: 321-332.CrossRef
Metadata
Title
Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
Authors
Laurent Coudeville
Fabrice Bailleux
Benjamin Riche
Françoise Megas
Philippe Andre
René Ecochard
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2010
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-10-18

Other articles of this Issue 1/2010

BMC Medical Research Methodology 1/2010 Go to the issue